Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at Cantor Fitzgerald

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

An analyst at a prominent research firm initiated coverage of the

Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on Lexicon Pharmaceuticals in a research note on Monday. They set an "overweight" rating and a $8.00 price objective on the stock.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up – What’s Next?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report)’s share price gapped up before the market opened on Monday. The stock had previously closed at $1.7950, but opened at $1.88. Lexicon Pharmaceuticals shares last traded at $1.9750, with a volume of 1,560,266 shares trading hands. Analyst Ratings Changes A number of research firms have commented on […]